Analysis
This week added three new data points to the fall 2026 IPO pipeline Pulse tracks on its stats page, even as its headline name kept slipping. Anthropic's IPO moved a second time, from an earlier October target to mid-October in early September, and now to November, still aimed at roughly a $2 trillion valuation. Meanwhile, ADARx priced concrete terms -- $15-$17 per share, up to $350 million, targeting a $1.74 billion valuation -- and TRex Bio and Retension Pharmaceuticals both filed fresh S-1s on the same day.
That spread -- one company slipping its timeline, one pricing concrete terms, two more just filing -- shows the pipeline moving at multiple stages simultaneously rather than frozen behind its biggest name. It also underscores a structural fact about this fall's window: none of the mega-cap AI listings have actually priced yet. OpenAI's own IPO has been pushed to 2027 entirely, which removes what would have been Anthropic's most direct same-sector pricing comparable -- Anthropic now has to stand on its own disclosed numbers when it finally lists, without a peer already trading to benchmark against.
“It also underscores a structural fact about this fall's window: none of the mega-cap AI listings have actually priced yet.”
The volume underneath the mega-caps is real: alongside ADARx and the two new biotech filings, Pulse's archive already tracks Nscale's public NYSE filing behind a $103 billion contracted backlog from earlier this month. The pattern so far this fall is consistent -- mid-cap biotech and specialty-insurance names are pricing and filing on schedule, while the largest, most-watched AI names keep sliding. Whether Anthropic's November date holds, and whether that becomes the actual pricing event that finally tests investor appetite for a $2 trillion AI IPO, remains the single biggest unresolved variable in the whole pipeline.